• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Neovacs SA - Product Pipeline Review - Q4 2010 - Product Image

Neovacs SA - Product Pipeline Review - Q4 2010

  • ID: 1446831
  • November 2010
  • 31 pages
  • Global Markets Direct

Neovacs SA – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Neovacs SA - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Neovacs SA - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Neovacs SA human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product READ MORE >



List of Tables
List of Figures
Neovacs SA Snapshot
Neovacs SA Overview
Key Information
Key Facts
Neovacs SA – Research and Development Overview
Key Therapeutic Areas
Neovacs SA – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Neovacs SA – Pipeline Products Glance
Neovacs SA Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Neovacs SA–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Neovacs SA – Drug Profiles
IFNa-kinoid
Product Description
Mechanism of Action
R&D Progress
TNFa-Kinoid
Product Description
Mechanism of Action
R&D Progress
VEGF Kinoid
Product Description
Mechanism of Action
R&D Progress
Neovacs SA – Pipeline Analysis
Neovacs SA – Pipeline Products by Therapeutic Class
Neovacs SA Pipeline Products By Target
Neovacs SA – Pipeline Products by Route of Administration
Neovacs SA – Pipeline Products by Molecule Type
Neovacs SA – Recent Pipeline Updates
Neovacs SA – Locations And Subsidiaries
Head Office
Recent Developments
Nov 15, 2010: Neovacs Receives DSMB Authorization To Proceed To Fourth Dose Level Of Ifna-Kinoid In Phase I/II Trial In Lupus
Sep 27, 2010: Neovacs Receives DSMB Approval For IFNa-Kinoid In Phase I/II Study In Lupus Patients
Jul 21, 2010: Neovacs Achieves Milestone With IFNa Kinoid Clinical Development Program For Treatment Of Lupus
Jul 21, 2010: Neovacs Achieves Milestone In Clinical Development Programs Of TNFa Kinoid For Treatment Of Rheumatoid Arthritis
Apr 21, 2010: Poster Illustrating Latest Promising TNFa Kinoid Clinical Data To Be Presented At DDW 2010 In New Orleans
Apr 21, 2010: Poster Illustrating Latest Promising TNFa Kinoid Clinical Data To Be Presented At DDW 2010 In New Orleans
Mar 29, 2010: Neovacs Successfully Enrolls First Patient In Its Phase II Clinical Study Of TNFa- Kinoid In Rheumatoid Arthritis
Dec 08, 2009: Neovacs Starts Phase II Clinical Trial Of TNFa Kinoid For Rheumatoid Arthritis
Nov 18, 2009: Preliminary Clinical Results From The Phase I/II Trial Of TNFa Kinoid In Crohn’s Disease To Be Presented At GASTRO 2009 In London
Jun 22, 2009: Neovacs Announces Positive Findings For TNF-a Kinoid
Financial Deals Landscape
Neovacs SA, Deals Summary, 2004 to 2010
Neovacs SA Detailed Deal Summary
Venture Financing
Neovacs Secures $17.92 Million In Venture Financing
Neovacs Secures $1.87 Million In Venture Financing
Licensing Agreements
Debiopharm Enters Into Licensing Agreement With Neovacs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS